Stockwinners Market Radar for October 18, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:18 EDT Cathie Wood's ARK Investment bought 48.6K shares of Nurix Therapeutics today

18:31 EDT Netflix says most people watch most movies at home - Says will take years to unwind COVID production logjam. Says theatrical release of "Glass Onion" a way to build hype for the Netflix release. Says most people watch most movies at home.

18:20 EDT Netflix says still not growing as fast as company would like - Says "all the stars are lining up" for the company. Says still not growing as fast as company would like. Says churn remains slightly elevated. Says saw acquisition growth across every region in Q3.

18:07 EDT Netflix says ad tier to attract new members - Says Q3 had "great examples" of "quality content." Says ad-supported tier likely to bring in new members. Says initial demand for ad-tier "very strong." Comments taken from Q3 earnings conference call.

17:38 EDT Don Lee Farms settlement with Beyond Meat reached, no party admits wrongdoing - As previously reported by Beyond Meat on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission on March 2, and on Form 10-Q for the fiscal quarter ended July 2 filed with the SEC on August 11 , Don Lee Farms and certain of its employees, on the one hand, and Beyond Meat, and certain of its respective current and former employees, on the other hand, were parties to litigation filed in the Superior Court of the State of California for the County of Los Angeles and the United States District Court for the Central District of California On October 18, the parties entered into a confidential written settlement agreement and mutual release, pursuant to which the parties agreed to dismiss all claims and cross-claims asserted in the State Court Case and Federal Court Case with prejudice. The terms of the settlement did not have a material impact on Beyond Meat's financial position or results of operations. No party admitted liability or wrongdoing in connection with the settlement. Both sides are satisfied with the outcome.

17:34 EDT BHP Group reports Q1 iron ore output 65.1MT, up 3% y/y - Reports Q1 copper production 410.1kt, up 9% y/y. Reports Q1 Metallurgical coal production 6.7MT, down 1% y/y. CEO Mike Henry states: "We have started the new financial year strongly, achieving safe and reliable operating performance. The first quarter included significant planned major maintenance in Western Australia Iron Ore (WAIO), BHP Mitsubishi Alliance (BMA), and Olympic Dam. Copper production was up nine per cent on the same quarter last year, with strong concentrator throughput at Escondida and record quarterly anode production at Olympic Dam. WAIO continued to perform strongly, with production up by 3% relative to the same period last year, and we managed through substantial rainfall and labor constraints in our coal assets with production only down marginally year on year. Our full year production and unit cost guidance is unchanged. The South Flank iron ore ramp-up and the Jansen potash project are tracking well, with work ongoing to bring forward first production from Jansen Stage 1 and accelerate Jansen Stage 2. During the quarter, BHP struck a new agreement to supply our WAIO port facilities with renewable electricity, which is expected to halve GHG emissions from the electricity used, signed an MoU with India's Tata Steel to collaborate on lower GHG emission steelmaking and announced a partnership with Pan Pacific Copper to reduce GHG emissions from maritime transportation, as we take further action to reduce GHG emissions from our operations and support decarbonisation of our suppliers and customers. We expect global macro-economic uncertainty in the short term to continue to affect supply chains, energy costs, labor markets and equipment and materials availability. BHP remains well positioned, with a portfolio and balance sheet to withstand external challenges and a strategy positioned to benefit from the global mega-trends of decarbonisation and electrification."

17:26 EDT Arch Capital estimates $530M-$560M in net catastrophe losses in Q3 - Arch Capital "reports that its Q3 results will be negatively impacted by the effects of Hurricane Ian, as well as from a series of other global events that occurred this year, including U.S. convective storms, Typhoon Nanmadol and the June French hailstorms. As a result, the Company has established a range of pre-tax catastrophe losses of $530 million to $560 million in the 2022 third quarter across its property casualty insurance and reinsurance segments, net of reinsurance recoveries and reinstatement premiums. The Company's estimate for Hurricane Ian is commensurate with a range of estimated insured losses across the global property/casualty insurance industry of $50 billion to $60 billion for this event, resulting in an approximate market share of industry losses for the Company that is comparable to prior natural events of a large magnitude. The losses are currently expected to be split approximately 70%/30% between the Company's reinsurance and insurance businesses, respectively."

17:08 EDT Denali Therapeutics drops 15% to $28.00 after $250M common stock offering

17:04 EDT Pinnacle Financial sees FY22 noninterest expense a high-teens percentage up - "We are very pleased with our PPNR results for the Q3" said Harold R. Carpenter, Pinnacle's CFO. "As to expenses, compensation costs increased approximately 15.6% over the same quarter last year, due primarily to increased opportunities to hire the best bankers and investment professionals in our markets. We are optimistic that our hiring model will continue to provide us even more opportunities to add revenue producers this year. Including the impact of inflation and the acquisition of JB&B Capital, in the Q1 of this year, our expenses, comparing the Q3 of 2022 to the same quarter in 2021, have increased by 18.0%. We now estimate our total 2022 noninterest expense should approximate a high-teens percentage increase over that of 2021."

17:03 EDT Intuitive Surgical raises FY22 procedure growth view to 17%-18% from 14%-16.5% - Refines FY22 gross profit margin view to 69%-69.5% from 69%-70.5%. Lowers operating expense growth view to 21%-23% from 23%-25%. Lowers FY22 capital expenditures view to $600M-$700M from $700M-$800M. Still sees FY22 tax rate 22%-24%. Says still experiencing staffing pressures at hospitals Says continues to see regional lockdowns occur as Covid cases rise in some areas. Comments and guidance taken from Q3 earnings conference call.

17:01 EDT Leafly to cut 56 positions as part of cost reductions - Leafly "announced a headcount reduction of 56 positions - or 21% of the company's workforce through a combination of layoffs and attrition - to ensure its long-term health. The company expects a one-time cash restructuring charge for the layoffs of approximately $500,000 in Q4 of 2022. In addition, the company has otherwise realigned its cost structure in response to changing market conditions, resulting in additional expected cost savings, for total expected annual cash savings of approximately $16 million beginning in 2023, primarily in headcount-related costs. These cost-cutting measures allow the company to prioritize growth opportunities, realign its expense structure, and preserve capital while strengthening its financial position."

16:46 EDT Bowman awarded Colorado's Department of Military and Veterans Affairs contract - Bowman Consulting announced that the State of Colorado's Department of Military and Veterans Affairs has awarded the firm a new contract in connection with the upgrade of security lighting at the Joint Forces Headquarters, or JFHQ, in Centennial, Colorado. Bowman will provide lighting design, electrical, civil and structural engineering under this award. This is part of a $1M upgrade to the facility. The lighting upgrades will be designed to meet current Army and Department of Defense lighting regulations and standards which dictate the use of extremely enhanced lighting systems to supplement security operations, including lighting for the use of closed-circuit television. Bowman has extensive experience designing security lighting upgrades at military sites across the State of Colorado.

16:39 EDT Greenlight Re Innovations invests in short-term rental insurance startup, Safely - Greenlight Re Innovations or GRI, of Greenlight Capital Re has announced an investment in SafelyStay. "With the rise of booking platforms such as Airbnb and Vrbo, the short-term home rental market has grown rapidly, and homeowners have become more aware of their homes' revenue-generating potential. However, concerns about the possibility of property damage and liability exposure have left many homeowners reluctant to list their properties. Safely addresses these friction points by screening each guest, reducing the likelihood that the homeowner will incur a loss. Safely also embeds commercial insurance protection directly into each reservation through its partnerships with property management systems. When a claim is made, the property manager can easily administer it within Safely's platform, which pays nearly all claims within two business days. Safely has accumulated more than two million nights' worth of data, building a robust view of risk factors within the short-term rental market and the broader sharing economy,"

16:31 EDT Vimeo reports 1% drop in YoY September subscribers - Reference Link

16:31 EDT Vimeo reports 1% drop in YoY September subscribers

16:23 EDT SeaSpine launches 7D FLASH Navigation System percutaneous spine module - SeaSpine Holdings announced the full commercial launch of the 7D FLASH Navigation System Percutaneous Spine Module. The release of the Percutaneous Module represents a new application and increased functionality for its 7D FLASH Navigation System, which now allows SeaSpine to further penetrate the minimally invasive spine surgery market, which SeaSpine estimates at approximately $4B worldwide. "The addition of the Percutaneous Module to the FLASH Navigation System has brought versatility to my OR," stated Dr. Douglas Orndorff of Spine Colorado. "Whether I am performing mini-open procedures, large revision surgeries, or MIS fusions, I can do them all with one system that optimizes my workflows depending on my approach. I'm also excited about the future launch of the Lumbar Facet Fusion system that will work seamlessly with the Percutaneous Module, enabling an integrated procedural solution for my patients."

16:20 EDT United Airlines sees FY22 capacity vs. 2019 approximately (13%) - Sees FY22 adjusted CASM-ex vs. 2019 ~15%; adjusted CapEx $4.7B.

16:19 EDT United Airlines sees Q4 capacity (9%)-(10%) vs. 2019 - Sees Q4 TRASM 24%-25% vs. 2019; adjusted CASM-ex 11%-12% vs. 2019; adjusted operating margin about 10%.

16:19 EDT Helmerich & Payne announces FY23 capex budget of $425M-$475M - The Company "has set its initial FY23 capex budget to range between $425M and $475M, representing a sizeable sequential increase and highlighting the capital-intensive nature of H&P's business as well as planned international expansion. H&P's North America Solutions segment accounts for approximately two-thirds of the expected spend as the Company plans to reactivate up to 16 idle rigs from its super-spec FlexRig(R) fleet, of which six rigs will be converted to a walking configuration and as maintenance capex per rig is expected to modestly exceed the high-end of the historic normalized range. The Company's International Solutions segment accounts for roughly a quarter of the planned expenditures in anticipation of reactivating more rigs during the fiscal year, upgrading five rigs in Argentina to super-spec and converting six additional super-spec rigs domiciled in the U.S. to walking configurations that are currently planned to be exported to international operations later in the fiscal year. The remainder of the fiscal 2023 capex budget is slated for corporate and information technology purposes as the Company continues to invest in and modernize its own operational and business-driven technologies."

16:17 EDT ContextLogic announces strategic partnerships with Moovin, Serpost - ContextLogic announced strategic partnerships with two Latin American logistics providers - Moovin in Costa Rica and Servicios Postales del Peru (Serpost) in Peru. The partnerships are set to reduce delivery times by more than 15 days, making Wish one of the fastest cross-border ecommerce platforms in both markets. "We have a unique opportunity in Costa Rica and Peru to become the go-to platform for users seeking to buy goods from abroad. Our partnership with Moovin and Serpost is an important first step in cementing our position as one of the leading cross-border platforms in the region," said Francisco Javier Miranda, Senior Manager of Logistics for Wish for Latin America. "We're excited to be partnering with two of the most trusted names in logistics in the region to help reduce delivery times and provide a better experience for our consumers."

16:14 EDT Laredo Petroleum sees Q4 CapEx $135M-$145M - Realized Pricing and Commodity Settlements. Realized prices for oil, NGL and natural gas for third-quarter 2022 were approximately $96.00 per barrel, $29.10 per barrel and $5.90 per Mcf, respectively. Net settlements paid for matured commodity derivatives for third-quarter 2022 totaled ~$125M . Capital Investments. Total incurred capital expenditures during the third quarter were ~$140M, excluding non-budgeted acquisitions and leasehold expenditures, higher than guidance of ~$120M Increased investments were related to the timing of drilling and completions activity and facilities/infrastructure build out. Fourth-quarter 2022 capital expenditures are expected to be $135 - $145 million, in-line with third-quarter 2022 levels.

16:13 EDT Bsquare to present plan to declassify the board of directors - Bsquare announced that it entered into a Cooperation Agreement with Richard Karp, a large shareholder. Pursuant to the Agreement the Company agreed to present a plan to declassify the board of directors to shareholders at the 2023 annual meeting of shareholders, tentatively planned for June 2023. The plan will seek to eliminate board classes in a phased manner over 3 years resulting in one year terms for all directors. The plan is not being presented at, and has no effect on, the annual meeting of shareholders scheduled to occur on November 29. In addition to the declassification plans, as a part of this Agreement, Karp has withdrawn his director nominees for the 2022 Annual Meeting.

16:12 EDT Laredo sees Q4 total & oil production 72.5-75.5 and 32.0 -34 MBOEPD respectively - The Company expects fourth-quarter 2022 total and oil production to be 72.5 - 75.5 MBOEPD and 32.0 - 34.0 MBOPD, respectively. Updated fourth-quarter expectations include revised assumptions related to the impact of offset operator completions, production downtime due to increased equipment lead times and an ~1.6 MBOEPD reduction in volumes related to the divestiture of non-operated acreage, which closed on October 3.

16:11 EDT United Airlines reports Q3 capacity down 9.8% vs. 3Q19 - Reports Q3: TRASM of up 25.5% compared to third quarter 2019; CASM of up 27.8%, and CASM-ex of up 14.5%, compared to third quarter 2019; operating margin of 11.3%, adjusted operating margin of 11.5%. Reported third quarter 2022 pre-tax margin of 9.0%, adjusted pre-tax margin1 of 8.9%.

16:09 EDT United Airlines expects Q4 adjusted operating margin to exceed 2019 level - Looking forward through the end of the year, the airline expects the strong COVID recovery trends to continue to overcome the recessionary pressures in the macroeconomic environment. The airline now expects fourth quarter adjusted operating margin to be above 2019 for the first time. The company also remains confident in the 2023 United Next adjusted pre-tax margin target of ~9%. The company believes there are three durable trends for air travel demand that are more than fully offsetting any economic headwinds: air travel is still in the COVID recovery phase, hybrid work gives customers the freedom and flexibility to travel for leisure more often, and external supply challenges will limit industry supply for years to come.

16:08 EDT Laredo Petroleum Q3 total production averaged ~79.5K MBOEPD - The Company's third-quarter 2022 total production averaged ~79.5 thousand barrels of oil equivalent per day or MBOEPD, within guidance of 78.5 - 81.5 MBOEPD. Oil production for the quarter averaged ~35.0 thousand barrels of oil per day , below guidance of 35.5 - 37.5 MBOPD. Oil production was negatively impacted as offset operator completions in Howard County affected more Laredo wells than expected. Of the impacted wells, newer, higher-production packages have returned to previous production expectations while older packages are taking longer than anticipated to return to expected production levels.

16:08 EDT Good Times Restaurants reports Q4 Good Times brand SSS up 5.9% - Good Times Restaurants announced that same store sales for its fourth fiscal quarter ended September 27, 2022 increased 5.9% for its Good Times brand and increased 3.7% for its Bad Daddy's brand, and that average weekly sales were $29,896 and $49,945 for its Good Times brand and for its Bad Daddy's brand, respectively, for the fourth fiscal quarter. For the full fiscal year, same store sales increased 1.1% for its Good Times brand and increased 11.2% for its Bad Daddy's brand, and average weekly sales were $27,974 and $49,425 for its Good Times and Bad Daddy's brands, respectively, for the full fiscal year. Ryan Zink, President and CEO, said, "The performance of both of our brands during the fourth quarter demonstrate the continuing dedication of our teams and the relevance of both of our brands in an extremely competitive environment. With year-over-year menu price increases that averaged approximately 7.7% for Good Times and 5.7% for Bad Daddy's during the quarter, our low single-digit traffic declines are favorable to what is being reported by Black Box Intelligence for the QSR and Casual Dining segments during the quarter. Our sales results are a direct result of restaurant managers overcoming persistent staffing challenges and all our people, at every level, thinking creatively to deliver exceptional service and high-quality products to our guests."

16:07 EDT American Woodmark invests $65M to expand capacity in North Carolina and Mexico - American Woodmark Corporation will increase its stock kitchen and bath cabinet capacity for east coast markets. The project will represent a total expected capital investment of approximately $65M over the next two years and result in the creation of more than 500 new jobs. The company expects to pay for this investment with cash on hand and borrowings from its revolving credit facility. "Our company strategy is focused on Growth, Digital Transformation and Platform Design or "GDP". Following a comprehensive review of our platform, we identified the need for additional capacity in our stock kitchen and bath cabinetry product lines. By adding a fourth facility in Mexico and expanding the Hamlet, North Carolina location, we will strengthen our overall supply chain and allow for incremental capacity in both categories on the east coast, which is one of the largest repair/remodel and new construction markets," said Scott Culbreth, President and Chief Executive Officer.

16:06 EDT Universal Insurance names William Degnan chief claims officer - Universal Insurance Holdings, Inc. announced that William Degnan has been appointed Chief Claims Officer. Degnan was previously Executive Vice President, Claims of Alder Adjusting Corporation, Universal's wholly owned claims adjusting subsidiary. Degnan will continue to lead enterprise-wide claims processing and adjusting, overseeing over 300 professionals and multiple third-party relationships. "William has been instrumental to our claims department, helping to develop a first class organization that allows us to better serve our policyholders," said Steve Donaghy, Chief Executive Officer. "William has spearheaded multiple initiatives, ultimately leading to increased customer satisfaction, and, under his leadership, we've increased technology adoption, leading to increased efficiency and productivity."

16:04 EDT Netflix says won't provide guidance for paid membership as of Q4 letter - Netflix said: "As discussed in previous letters, we are increasingly focused on revenue as our primary top line metric. This will become particularly important heading into 2023 as we develop new revenue streams like advertising and paid sharing, where membership is just one component of our revenue growth. So, starting with our Q4'22 letter in January of 2023, we'll continue to provide guidance for revenue, operating income, operating margin, net income, EPS and fully diluted shares outstanding for the following quarter, but not paid membership. Similar to our regional membership disclosure, we'll continue to report our global and regional membership each quarter as part of our earnings release."

16:03 EDT Micro Focus shareholders approve acquisition by OpenText - OpenText confirms that shareholders of Micro Focus International approved the terms of the recommended all-cash offer by OpenText, through its wholly-owned subsidiary, Open Text UK Holding Limited, to acquire the entire issued and to be issued share capital of Micro Focus and as announced on August 25.

16:02 EDT PTC Therapeutics begins enrollment for Phase 2 PIVOT-HD trial of PTC518 - PTC Therapeutics confirmed that enrollment is active and ongoing for its Phase 2 PIVOT-HD trial of PTC518 for the treatment of Huntington's disease at study sites globally. To date, PTC has received approval for conduct of the planned 12-month study in several European countries as well as Australia. The Phase 2 PIVOT-HD study consists of two parts; an initial 12-week placebo-controlled part focused on PTC518 pharmacology and pharmacodynamic effect, followed by a 9-month placebo-controlled part, during which blood, CSF, and radiographic biomarker data will be collected. The study will initially include two dose levels, 5 milligrams and 10 milligrams, with the potential to study a third dose leveraging the titratability of the drug. The approvals received to date for the 12-month study include both the 5mg and 10mg dose levels, as well as a potential third dose pending the results of the first two dosing cohorts. Enrollment in the 12-week portion of the study began first in the US and continues globally. To date there have been no treatment-related adverse events reported in the US or outside of the US. However, the FDA has requested additional data to allow the study to proceed in the US. Accordingly, enrollment in the US has been paused while discussions with the FDA continue towards resuming US enrollment. PTC is working towards sharing data from the 12-week portion of PIVOT-HD within the first half of 2023.

15:33 EDT Enbridge CEO Al Monaco retires, Greg Ebel to succeed - Enbridge recently announced Al Monaco's retirement as President and CEO and from its Board of Directors effective January 1, 2023. Concurrent with this announcement and after considering internal and external candidates, the Board of Directors has appointed Greg Ebel, currently Board Chair, to succeed Monaco as President and CEO. Ebel will also continue as a member of the Board of Directors. A new independent Board Chair will be named prior to January 1, 2023. To support Ebel through the transition, Monaco will serve as an advisor to March 1, 2023. Since 2017, Ebel has held the position of Chair of the Board which has, along with the Board, provided strategic oversight and leadership to the Company throughout its ongoing transformation.

15:10 EDT Activision confirms Modern Warfare 2 pre-load, early access times - Activision said in a release: "The release of Call of Duty: Modern Warfare II is just around the corner as we rapidly approach its October 28 launch date on PC. In partnership with Infinity Ward, Call of Duty PC lead developer Beenox shares some of the highlights coming to the PC version of the game...Preloading for Campaign early access on PC begins October 19 at 10 AM PT, with early access going live the next day on October 20 at 10 AM PT. Play alongside the members of Task Force 141, the Mexican Special Forces, and Shadow Company up to a full week before launch while earning Campaign completion unlocks that can be used in Multiplayer and Special Ops at launch.Preloading for the game's official launch, including Multiplayer and Special Ops, begins on October 26 at 10 AM PT, with the full title going live on October 27 at 9 PM PT." Reference Link

14:06 EDT Electronic Arts says new 'Sims' game currently in development - Electronic Arts said that the team behind the "Sims" franchise is building the next generation game and creative platform, reimagining "The Sims" with even more new ways to play. The game, which is currently in its very early stages of development, has a working title "Project Rene." "This name was chosen to be reminiscent of words like renaissance and rebirth to represent the team's renewed commitment for The Sims' bright future," EA said. "Project Rene will fundamentally evolve how Sims think and behave, how players create and customize their worlds, and innovate in entirely new ways. To start, we are experimenting with creative tools, a key part of The Sims' DNA, and taking a look at what has worked before and how we can offer more flexibility to help with building and decorating in-game. With Project Rene, players will have the choice to play solo or collaborate with others, and will have the ability to play their game across supported devices." Reference Link

13:43 EDT Rolls-Royce unveils its first electric car, the Spectre - Reference Link

12:40 EDT NJ sues oil companies for misleading public about climate change - New Jersey Attorney General Matthew Platkin, the New Jersey Division of Consumer Affairs and the Department of Environmental Protection today filed a lawsuit on behalf of New Jersey residents against five oil and gas companies and a petroleum trade association, alleging "they knowingly made false claims to deceive the public about the existence of climate change and the degree to which their fossil fuels products have been acerbating anthropogenic global warming." The suit names as defendants Exxon Mobil (XOM), Shell Oil (SHEL), Chevron (CVX), BP (BP), ConocoPhillips (COP), and the trade group in which these defendants were members - American Petroleum Institute. In addition to asking the court for an injunction ordering the energy companies to "stop deceiving New Jersey consumers about the destructive environmental impacts of fossil fuels," the state is seeking civil monetary penalties and damages, including natural resource damages. According to the complaint, the oil and gas companies researched the link between fossil-fuel consumption and climate change starting as early as the 1950s, and by the mid-60s "gained a comprehensive understanding of the adverse climate impacts of fossil fuels." However, according to the complaint, the defendant oil and gas producers "worked to manufacture doubt about the existence and causes of climate change." Reference Link

12:01 EDT Rubric reiterates call for board change at Mereo after operating plan update - Rubric Capital Management, an investment advisor whose funds and accounts collectively own approximately 14% of the outstanding equity of Mereo BioPharma, issued the following statement in response to the Company's updated operating plan: "We commend Mereo management for heeding our call for action and taking the painful but necessary step of streamlining operations in order to preserve cash. At the time of the alvelestat data release in May through today, Mereo has improved its cash runway by two years and refocused resources on its most valuable programs. Unfortunately, in the second quarter alone, Mereo burned approximately GBP 9 million of cash, which the company clearly recognizes is unsustainable. We do not believe this action would have been taken without Rubric's public engagement and, while this step is encouraging, we believe there is more work that can be done to unlock value at Mereo. Mereo's actions today confirm that our proxy contest has shaken the boardroom of Mereo off the autopilot it has been operating on for years, but this is not enough - active corporate governance paired with direct alignment with shareholders is necessary to achieve maximum value. Rubric's slate of director nominees is highly qualified to drive further necessary change that is in the best interests of shareholders. We look forward to the general meeting and encourage all shareholders to vote in order to achieve further value enhancement led by our nominees."

12:00 EDT ServisFirst falls -12.7% - ServisFirst is down -12.7%, or -$11.07 to $75.78.

12:00 EDT Carnival rises 8.8% - Carnival is up 8.8%, or 64c to $7.91.

12:00 EDT Natura &Co rises 14.3% - Natura &Co is up 14.3%, or 70c to $5.58.

11:42 EDT Inpixon trading resumes

11:27 EDT State Street raises FY22 NII view to up 28%-30% from up 24%-27%

11:15 EDT Krispy Kreme up 8% after reports of McDonald's testing donut sales partnership - Shares of Krispy Kreme (DNUT) are up 8% to $13.98 after McDonald's (MCD) is reported to have said it will start a test of selling three varieties of Krispy Kreme doughnuts at nine locations in restaurants in Kentucky

11:08 EDT State Street says remains focused on controlling expense growth - Says global operating environment continues to be challenging. Says continues to carefully navigate business for environment. Says maintained strong balance sheet and capital position. Says business momentum was solid in Q3. Says remain excited by global advisor strategy. Comments taken from Q3 earnings conference call.

11:05 EDT Lockheed Martin expects 'solid' growth in FCF in 2023 and thereafter

11:04 EDT Lockheed Martin 'on track' to hit FY outlook for all financial metrics - Comments taken from Q3 earnings conference call.

11:01 EDT Apple introduces next generation iPad Pro - Apple announced the new iPad Pro with the M2 chip. The iPad Pro "delivers the ultimate combination of portability, versatility, and unbelievable performance. The new iPad Pro features a next-level Apple Pencil hover experience and superfast wireless connectivity, along with the world's most advanced mobile display, pro cameras, Face ID, Thunderbolt, and a four-speaker audio system. New features in iPadOS 16 - including Stage Manager, full external display support, desktop-class apps, and Reference Mode - take pro workflows on iPad even further. Enabled by its advanced hardware and iPadOS 16, iPad Pro has an incredible ecosystem of powerful pro apps unlike any other device of its kind. The new iPad Pro is available to order starting today, and in stores beginning Wednesday, October 26."

10:52 EDT Peloton Chief People Officer Shari Eaton to leave company - Peloton's Chief People Officer Shari Eaton is leaving the company for another opportunity, she announced in a LinkedIn post Tuesday. Eaton said: "To John Foley, Hisao Kushi, Tom Cortese, and the rest of the founders - the vision, mission and values you architected have created a very special culture and one I have been honored to nurture during my time as a team member... Thank you Barry McCarthy for believing in me and trusting me to work alongside you during this important transformational time. I will continue to be a passionate cheerleader, member, and shareholder of this company. I do not want my departure to call into question how much I believe in the power of this brand and the goodness it brings to 7 million members worldwide." Reference Link

10:23 EDT Holcim says Lafarge to pay $778M to Justice Department for terrorist support - Holcim said its supports the agreement reached by Lafarge with the U.S. Department of Justice to resolve the DOJ's inquiry into Lafarge and its "long-defunct" subsidiary Lafarge Cement Syria "related to the legacy conduct" of certain former executives during the Syrian civil war, before Holcim acquired Lafarge SA. Under the terms of the resolution, Lafarge SA and Lafarge Cement Syria will pay a financial penalty of $777.78M and have agreed to plead guilty to one count of conspiring to provide material support to designated foreign terrorist organizations in Syria between August 2013 and October 2014. "None of the conduct involved Holcim, which has never operated in Syria, or any Lafarge operations or employees in the United States, and it is in stark contrast with everything that Holcim stands for. The DOJ noted that former Lafarge SA and LCS executives involved in the conduct concealed it from Holcim before and after Holcim acquired Lafarge SA, as well as from external auditors," the company said in a statement.

10:18 EDT Starboard's Smith says Salesforce should be at same margins as peers or higher - Starboard Value's Jeff Smith, who has taken a stake in Salesforce, continues being interviewed by CNBC's David Faber from the 13D Monitor conference.

10:06 EDT GameStop chairman Cohen posts picture with Carl Icahn - GameStop chairman Ryan Cohen posted last night on Twitter a picture of him and activist investor Carl Icahn. Shares of GameStop are up 3% to $26.73 in morning trading. Reference Link

10:03 EDT Utz Brands expands portfolio of snack foods to all 112 Schnucks stores - Utz Brands is pleased to expand its portfolio of snack foods to all 112 Schnucks stores. Schnucks, a leading grocery retailer, has stores conveniently located throughout Missouri, Illinois, Indiana, and Wisconsin.

10:02 EDT Izea announces launch into UK market - IZEA Worldwide announced its launch in the UK market. IZEA President and Chief Operating Officer Ryan Schram said: "The influencer industry in the UK, as in many other markets, has tremendous growth potential, but lacks the expertise and innovation required by top marketers. We'd like to be instrumental in helping it structure for even greater success to better serve brands, agencies, and creators. Providing all of our clients with flexible access to influencer services and detailed performance data sits at the heart of how IZEA does things. Insights from the nearly four million collaborations we have run give us a powerful level of predictive analysis and the ability to guarantee results."

10:00 EDT ServisFirst falls -8.7% - ServisFirst is down -8.7%, or -$7.59 to $79.26.

10:00 EDT AG Mortgage rises 13.5% - AG Mortgage is up 13.5%, or 51c to $4.30.

10:00 EDT Natura &Co rises 17.0% - Natura &Co is up 17.0%, or 83c to $5.71.

09:51 EDT Kiora Pharmaceuticals Inc trading resumes

09:47 EDT Direxion Financial Bear 3x falls -7.1% - Direxion Financial Bear 3x is down -7.1%, or -$1.79 to $23.52.

09:47 EDT Silvergate Capital falls -10.3% - Silvergate Capital is down -10.3%, or -$7.26 to $63.53.

09:47 EDT FuboTV rises 12.8% - FuboTV is up 12.8%, or 52c to $4.57.

09:45 EDT Colgate-Palmolive up 3% after CNBC says Third Point built stake - Shares of Colgate-Palmolive are up $2.00, or 3%, to $74.14 following David Faber's on-air reporting about activist Dan Loeb's stake.

09:41 EDT Gravitas Education Holdings trading resumes

09:36 EDT Gravitas Education Holdings trading halted, volatility trading pause

09:35 EDT Kroger opens Customer Fulfillment Center in Romulus, Michigan - The Kroger Co. (KR) announced the official opening of its newest Customer Fulfillment Center in Romulus, Michigan. Powered by the Ocado Group (OCDGF), the CFC will leverage advanced robotics technology and creative solutions to redefine the customer experience for customers in the greater Detroit area. The approximately 135,000-square-foot facility, situated on Wahrman Road in Romulus, will reach customers up to 90 minutes from the site. The new customer fulfillment center will employ more than 700 associates as Kroger Delivery continues to expand its services throughout southeast Michigan.

09:33 EDT National CineMedia, Spotlight Cinema Networks collaborate to launch Elevate - National CineMedia and Spotlight Cinema Networks announced a strategic sales relationship, the Elevate Cinema Network. This collaboration will combine nearly 1,500 premier NCM screens with Spotlight's existing premier network of over 1,200 screens to bring Elevate's network to 2,700 'blue chip' screens available for cinema advertising through Spotlight. Elevate will provide unprecedented reach and recall to brands targeting the upscale, educated, adult demographic with disposable income.

09:32 EDT Goldman Sachs CEO: Global economy facing 'significant' headwinds - Comments taken from Q3 earnings conference call.

09:30 EDT Johnson & Johnson remains 'really confident' in growth expectations - Says breadth of portfolio bodes well for continued growth. Sees "above market growth" in FY23 from Pharmaceutical unit. Says M&A priorities have not changed.

09:18 EDT Liquid Media reports Q3 revenue $1.53M vs. $5,365 last year - CEO Joshua Jackson comments, "We continue to execute on our ambitious business plan, leveraging success with our subsidiary companies as well as key partnerships. Continued strong revenue from DCU and iNDIEFLIX along with new offerings from IgemsTV and Projektor continue to expand our ability to provide resources to our customers and help independent creators navigate through the full lifecycle of intellectual property. We expect to continue to create new avenues for our customers to share their creations alongside new opportunities to bring shareholder value through our multi-pronged approach, and we look forward to continuing to report on the successes of our subsidiaries, partners and clients."

09:17 EDT Energem Corp. urges stockholders to vote in favor of extension amendment - Energem announced the filing of a definitive proxy statement on October 17, 2022, to hold an extraordinary general meeting of shareholders to: amend the Company's amended and restated articles of association to extend the period of time for the Company to complete a business combination up to nine times, each by an additional one month for an aggregate of nine additional months or such earlier date as determined by the board of directors; and amend the investment management trust agreement between Continental Stock Transfer & Trust Company, as trustee and the Company governing the trust account established in connection with the closing of Energem's initial public offering on November 18, 2021, to extend the date on which Continental must liquidate the Trust Account if the Company has not completed its initial business combination, from November 18, 2022 to August 18, 2023. The Extraordinary General Meeting to approve the Extension Amendment will be held virtually at 9:00 a.m. Eastern Time on November 11, 2022.

09:15 EDT Splash Beverage's TapouT to be sold through New Mexico's Admiral Beverage - Splash Beverage Group announced that its TapouT performance drink will now be distributed across the state of New Mexico through Wyoming-based Admiral Beverage Corporation. Founded more than 50 years ago, Admiral Beverage and its related companies produce and distribute premium soft drinks, waters, teas, fruit juices, energy drinks, alcoholic beverages and more, through sales offices and distributorships in more than 9 states. TapouT will initially receive full state coverage across Admiral's New Mexico distribution network.

09:10 EDT Broadcom showcases hyperscale solutions at 2022 OCP Global Summit - Broadcom announced its continued commitment to open computing by demonstrating a host of industry-first solutions addressing AI/ ML workloads at scale at the 2022 OCP Global Summit, being held October 18-20 at the San Jose Convention Center. A long-time supporter of open, standards-based technologies, Broadcom is dedicated to developing high-performance, scalable connectivity solutions optimized for AI/ML in hyperscale data centers.

09:09 EDT Oscar Health announces HCA Midwest Health as in-network provider - Oscar Health announces as an in-network provider HCA Midwest Health, the area's largest healthcare provider. HCA Midwest Health will help expand coverage for more individuals across the Kansas City region during Open Enrollment season and will bring HCA Midwest Health providers and facilities in-network for Oscar's individual and family health insurance plans beginning January 1, 2023. "Since our founding, Oscar's mission has been to broaden access to high-quality, affordable healthcare to individuals across the country," said Dennis Hillen, Senior Vice President at Oscar. "As we enter our fourth year in the Kansas City ACA marketplace, we're proud to have HCA Midwest Health meaningfully expand our network reach and make that vision a reality for more people in the Kansas City area."

09:09 EDT Merck Animal Health launches Animo GPS in U.S. - Merck Animal Health, a division of Merck & Co, announced the U.S. launch of Animo GPS, an activity and behavior monitor for dogs with GPS tracking capabilities. The product can alert pet owners within 20 seconds if their dog leaves its designated "Safe Zone" and offers real-time tracking with location updates from every five seconds when in "Lost Dog Mode."

09:07 EDT Trivago enters global partnership with AXS - trivago and AXS announced a global partnership "combining a love for travel and live entertainment," the company said. The partnership, which was developed by AEG Global Partnerships, makes trivago the exclusive accommodation partner of AXS. As part of the agreement, an interactive, trivago branded accommodation search engine will be made available on AXS.com, which will assist ticket buyers with finding the best place to catch some Zzz's after their festivities have concluded. Upon purchasing an event ticket, AXS users can take their fan experience to the next level by searching for a stay nearby via trivago and seamlessly booking accommodations near their event. "We are thrilled to announce trivago's partnership with AXS. It's exciting to see people back out in the world, doing the things they love most," said trivago CEO, Axel Hefer. "As the exclusive accommodation partner to AXS, we look forward to helping enhance every customer's experience and night out with great hotel and booking deals."

09:04 EDT BYND received initial approval to engage in medical cannabis in Israel - BYND Cannasoft Enterprises announced that it received initial approval to engage in medical cannabis without direct contact with the substance from the Medical Cannabis Unit at the Ministry of Health of the State of Israel. Cannasoft received this initial approval as part of the process to obtain a full license that allows trading in medical cannabis products through an agreement with a licensed cannabis grower in Israel. Cannasoft is in the final stage of obtaining the full license. Upon receipt of the full license, Cannasoft intends to immediately implement and execute an agreement with a licensed Israeli grower to produce and distribute various medical cannabis products that constitute the Company's private brand for all pharmacies and pharmacy chains in Israel. Yftah Ben Yaackov, CEO and Director of BYND, said, "We anticipate that as long as there are no unforeseen circumstances, Cannasoft will receive a full license to engage in medical cannabis without direct contact in the near future. Our strategy post-license will be to penetrate the cannabis products market in Israel and globally immediately after the approval of the Israeli regulator for the export of cannabis products from Israel. Our business plan allows us to accomplish this without investing heavily in resources and establishing and operating cultivation facilities." Mr. Yaackov continued, "In this way, BYND Cannasoft will be able to realize its goal of generating significant revenues from the sale of cannabis products while saving significantly on the Company's expenses for this purpose."

09:03 EDT NXP Semiconductors announces OrangeBox development platform - NXP Semiconductors announced the OrangeBox automotive-grade development platform, which integrates a wide variety of NXP wireless technologies, from broadcast radio, Wi-Fi 6 and Bluetooth, to secure car access with Ultra-Wideband and Bluetooth Low Energy, and 802.11p-based V2X. The OrangeBox is a single, security enhanced, modular development platform that provides a unified interface between the vehicle's gateway and its wired and wireless technologies. By doing so, it provides a means for next-generation cars to securely communicate with the world around them.

09:02 EDT Caribou presents report on long-term follow up from patient dosed with CB-010 - Caribou Biosciences announced the presentation of a case report for long-term follow up on the first patient dosed in its ANTLER Phase 1 clinical trial for CB-010 in relapsed or refractory aggressive B cell non-Hodgkin lymphoma. A recent evaluation showed the patient has maintained a complete response at 15 months after a single dose of CB-010. The poster presentation provides long-term data for the first patient treated in the ANTLER Phase 1 clinical trial with a single dose of CB-010 administered at dose level 1. The patient is a 66-year-old male, diagnosed in 2013 with aggressively behaving follicular lymphoma, demonstrating progression of disease within 24 months. Before joining the ANTLER trial, the patient had received eight prior lines of systemic anti-cancer therapy. After a single dose of CB-010, the patient initially demonstrated a CR at 28 days, which has been maintained through his 15-month evaluation. "The 15-month CR for the first patient in the ANTLER trial exceeded our expectations at this initial dose level and we are highly encouraged by this outcome as we aim to set a new therapeutic bar for patients with relapsed or refractory B-NHL," said Rachel Haurwitz, Ph.D., Caribou's president and chief executive officer. "There is a significant unmet need for an allogeneic cell therapy that can rival the efficacy of autologous cell therapies. We believe that the safety and efficacy profile of CB-010 at dose level 1 has laid the foundation for the promise of this off-the-shelf cell therapy to meet that patient need. As we continue enrollment in the ANTLER trial, our goal is to build upon this foundation by assessing CB-010's safety and durability at a higher dose level."

09:02 EDT Darling Ingredients to acquire Brazilian collagen producer Gelnex for $1.2B - Darling Ingredients has entered into a definitive agreement to acquire all of the shares of Gelnex, a global producer of collagen products, for approximately $1.2B in cash. The transaction is subject to customary regulatory approvals and is anticipated to close in 1Q23. Headquartered in Brazil with five facilities in South America and one in the U.S., Gelnex has the capacity to produce 46,000 metric tons of collagen products annually, which it exports to more than 60 countries around the world, and employs about 1,200 employees.

08:56 EDT State Street says winning new business across client segments, geographies - Says new mandates driven by broad based wins across client segments. Says Q3 Fee revenue down largely due to lower equity and fixed income market levels. Says Q3 saw business momentum across Front office software and data services. Says continued y-o-y servicing fee momentum in Alternatives despite equity and fixed income market volatility. Comments taken from Q3 earnings presentation slides.

08:49 EDT Microbot Medical submits follow-up pre-submission package for LIBERTY System - Microbot Medical announced that it has submitted the anticipated follow-up pre-submission package for the LIBERTY Robotic System to ensure the Company remains fully aligned with the U.S. Food and Drug Administration as it prepares for its Investigational Device Exemption submission and first-in-human clinical trial with the system in 2023.

08:48 EDT Quest Diagnostics collaborates with Decode Health for research platform - Quest Diagnostics announced a new phase of its collaboration with Decode Health, a healthcare AI company, that aims to empower drug and diagnostics research and development in the fields of metabolic disease and autoimmune neurology. In earlier phases of the collaboration, the two parties developed RNA sequencing capabilities based on both parties' sequencing, analytics and clinical expertise. In this latest phase, the parties have developed a national platform for collecting and storing deidentified consented specimens from individuals participating in research. The platform includes Quest's 2,100 patient service centers as well as its ExamOne mobile in-home phlebotomy team and a biobank at its laboratory in Memphis, Tenn. Quest and Decode will share benefits from any research, data licensing, biomarker discovery or diagnostics development that emerge. Additional terms were not disclosed. At this stage of the collaboration, Decode and Quest's initial focus is on addressing a pressing need for earlier detection, differential diagnosis and therapy selection for multiple sclerosis. As the collaboration progresses, the parties plan to expand to additional clinical disease areas.

08:48 EDT EU passenger car registrations up 9.6% in September - In September, new passenger car registrations in the European Union rose by 9.6%, "marking the second consecutive month of growth this year," said the European Automobile Manufacturers Association. "However, this increase was largely driven by the low base of comparison from September 2021, when the semiconductor shortage hampered vehicle production," the group stated. Publicly traded automakers include Ford (F), General Motors (GM), Honda (HMC), Mercedes-Benz Group (DDAIF), Nissan (NSANY), Stellantis (STLA), Tesla (TSLA), Toyota (TM) and Volkswagen (VWAGY). Reference Link

08:45 EDT Gilead gives new data from HIV R&D programs at at HIV Glasgow 2022 - Gilead Sciences announced the company's upcoming new data from its HIV research and development programs to be presented at the 30th International Congress on Drug Therapy in HIV Infection, HIV Glasgow 2022, in Glasgow, Scotland and virtually from October 23-26. Gilead will present data supporting its current and pipeline innovations in HIV treatment and the latest research from its ongoing cure development program, reflecting the company's innovative approach to continuous scientific discovery. "Continued scientific innovation and inclusive approaches are essential in the discovery and development of person-centred options that address the evolving needs of a broad range of individuals and communities affected by HIV," said Jared Baeten, MD, PhD, Vice President, HIV Clinical Development, Gilead Sciences. "The data presented at HIV Glasgow reflect the latest progress in our research and development programs and underscore Gilead's commitment to driving transformational innovation in HIV research. Our goal, together with the broader HIV community, is to end the HIV epidemic for everyone, everywhere. We look forward to connecting in person in Scotland at this year's meeting and sharing these data with the scientific community as we work towards this important goal."

08:43 EDT Charah Solutions appoints Jonathan Batarseh as CFO - Charah Solutions (CHRA) announced the appointment of Jonathan Batarseh as CFO and Treasurer, effective October 17, 2022. Mr. Batarseh, who will report to CEO and President Scott Sewell, is responsible for overseeing accounting, financial planning and analysis, tax, treasury, investor relations, information technology, fleet, and procurement initiatives. He joins Charah Solutions from Brown & Root Industrial Services, a joint venture between KBR (KBR) and Bernhard Capital Partners, where he was CFO, responsible for overseeing all financial management and reporting, treasury, and information technology and services.

08:40 EDT Vectivbio announces closing of $125M underwritten offering of ordinary shares - VectivBio Holding announced the closing of its previously announced underwritten offering of 16,700,000 ordinary shares at an offering price of $7.50 per share. Investors who purchased shares in the offering include Cowen Healthcare Investments, Driehaus Capital Management, Eventide Asset Management, LLC, Forbion's Growth Opportunities Fund, Frazier Life Sciences, Marshall Wace, OrbiMed, Surveyor Capital, TCG X, Venrock Healthcare Capital Partners and Vivo Capital, among other specialist biotech investors. Before deducting the underwriting discounts and commissions and offering expenses, VectivBio received total gross proceeds of approximately $125M. VectivBio intends to use the net proceeds from the offering, together with its existing cash and cash equivalents: to fund clinical development and pre-commercialization activities for its lead product candidate and general corporate purposes, including general and administrative expenses and working capital. Jefferies, SVB Securities and Piper Sandler acted as the joint book-running managers for the offering.

08:38 EDT BTCS announces $100,000 investment in GlobexUS Holdings - BTCS announced a $100,000 strategic investment in GlobexUS Holdings Corp; the parent of Horizon Globex GmbH, the technology provider and joint venture partner of the Upstream exchange. "Over the last eight years, BTCS has been on the cutting edge of U.S. public companies in the blockchain sector," said Charles Allen, Chief Executive Officer of BTCS. "Ethereum remains core to BTCS as our largest digital asset holding for which we currently run 240 validator nodes with over 8,400 ETH staked. While Ethereum is widely known as a platform to deploy NFTs, it has much broader use cases, such as the trading of securities. As an infrastructure provider, our investment in an Ethereum-based layer 2 application not only showcases the power of blockchains but the potential of BTCS' future. As the first U.S. publicly listed company to issue a dividend payable in Bitcoin earlier in 2022, potential tokenization and dual listing of our shares on Upstream's platform would highlight our further utilization of disruptive blockchain capabilities that support our belief in the fast-growing industry," continued Allen.

08:37 EDT Duck Creek Technologies announces cloud-based integration with ExamWorks - Duck Creek Technologies announces a cloud-based integration with ExamWorks' U.S. IME division to offer Independent Medical Examinations to P&C and legal customers. "We are thrilled to partner with a leading provider of independent medical exams and offer Duck Creek customers a more seamless IME experience," said Elaine Rogalla, Sr. Product Manager, Duck Creek Technologies. "The claims lifecycle is a core insurance process, and we are committed to partnering with industry leaders who help enable a simple and consistent workflow for our customers."

08:35 EDT Aptar, Chiesi sign digital health deal for platform for Asthma, COPD patients - Aptar Digital Health announced a strategic partnership with the Chiesi Group, the international research-focused biopharmaceutical and healthcare group, to bring to market a disease management platform for asthma and chronic obstructive pulmonary disease COPD . Aptar Digital Health is a division of Aptar Pharma, part of Aptar. The partnership will leverage Aptar's recently announced Disease Management Platform that is designed to empower patients to better understand and take control of their disease, provide healthcare professionals with data-driven insights to better manage their patients and build evidence for emerging reimbursement arrangements in the field of digital health for asthma and COPD. The platform offers a comprehensive set of services and solutions aimed at bringing together both the pharmacological and behavioral aspects of managing respiratory diseases, such as adherence monitoring, lung function assessment, reporting symptoms, identifying disease triggers and communication with care teams and health coaches. The partnership initially focuses on Europe, with potential future expansions to other geographies.

08:35 EDT Tomi's SteraMist to be used in global influenza vaccine facility in Australia - TOMI Environmental Solutions announced that SteraMist is to be utilized by a world-renowned influenza vaccine company that focuses on innovative research, transformative technologies, production, and distribution. TOMI's Australian partner, Critical Scientific Solutions, was recently awarded the $280,000 purchase order in the third quarter of this year for three modified SteraMist Environment Systems and TOMI's stainless steel 90-degree applicators to be used in this prestigious influenza vaccine company's labs to decontaminate their cleanrooms and penetrate HEPA filters to decontaminate ductwork. Elissa Shane, COO of TOMI, stated, "Since their initial purchase late last year, Critical Scientific Solutions has been a steadfast partner and service provider, able to enter the Australian and New Zealand markets quickly with an understanding of the advantages of SteraMist technology and a targeted focus in the Life Sciences. We are looking forward to pursuing future opportunities through this valuable partnership. We continue to see strong demand for our custom engineered systems in the Life Science sector which provides an expanding base of stable and recurring BIT solution demand over the life of the systems."

08:33 EDT Quoin announces plans to initiate second trial in Netherton syndrome patients - Quoin Pharmaceuticals announces that it is initiating a second clinical trial in Netherton Syndrome patients. This multicenter, open label study will be being conducted under Quoin's currently open U.S. Investigational New Drug, IND, Application and will assess QRX003 topical lotion in Netherton patients who are currently receiving treatment including systemic therapy for symptomatic relief. QRX003 will be applied once daily over a twelve-week period, to pre-designated areas of the patient's body. A number of different clinical endpoints will be assessed in the study. Quoin CEO, Dr. Michael Myers, said, "We are very pleased to announce our plan to initiate this second clinical study in Netherton patients under our open IND application. While there are no currently approved therapeutic treatments for Netherton Syndrome, we are aware that a subset of patients is being treated off-label with systemic biologics, including systemic therapy, that provide some symptomatic relief but do not address all symptoms, nor the underlying cause of the disease."

08:32 EDT Taoping enters into strategic cooperation with Jiangsu SuLiXin - Taoping's wholly owned subsidiary, Taoping Digital Tech Jiangsu, entered into a three-year strategic cooperation agreement with Jiangsu SuLiXin Cultural. Under the agreement, SuLiXin will purchase display terminals and services from Taoping, with the two companies also agreeing to jointly develop larger scale digital multimedia exhibition hall projects across China. Specifically, SuLiXin plans to purchase at least RMB30M, or $4.2M, of equipment from Taoping during the term of the agreement. Taoping will be recognized as a strategic partner to SuLiXin and the main supplier of DLP, LCD, LED and other large display screens required for its larger scale, digital multimedia exhibition hall projects. Taoping has agreed to leverage the channel advantages of its proprietary city partners network to actively help promote the development of SuLiXin's various other cultural exhibition hall project businesses in the national market, especially in East China.

08:29 EDT Mynaric to provide optical communications terminals to Northrop Grumman - Mynaric (MYNA) announced it will provide Northrop Grumman (NOC) with optical communications terminals for 14 satellites as part of the Space Development Agency's or SDA Tranche 1 Tracking Layer program. Each satellite will feature a wide field-of-view infrared sensor, three optical communications terminals, and a Ka-band payload for communications. Mynaric will supply 42 CONDOR Mk3 terminals to Northrop Grumman for the program with the product deliveries expected mostly in 2024 for deployment in 2025. "Once again, we are proud to support Northrop Grumman and the SDA on this program which is critical to the United States' national defense," said Mynaric Chief Commercial Officer Tina Ghataore. "This announcement highlights our commitment to delivering products for space applications that are technically sound and can be serially produced. We will leverage our experience working with Northrop Grumman on the Tranche 1 Transport Layer as we embark on the delivery of the terminals for the Tranche 1 Tracking Layer satellites."

08:26 EDT Mynaric to provide optical communications terminals to Northrop Grumman - Mynaric (MYNA) announced it will provide Northrop Grumman (NOC) with optical communications terminals for 14 satellites as part of the Space Development Agency's Tranche 1 Tracking Layer program. Each satellite will feature a wide field-of-view infrared sensor, three optical communications terminals, and a Ka-band payload for communications. Mynaric will supply 42 CONDOR Mk3 terminals to Northrop Grumman for the program with the product deliveries expected mostly in 2024 for deployment in 2025.

08:26 EDT Mill City provides short-term funding to facilitate podcast platform merger - Mill City Ventures III announced it has provided $2.225M of short-term debt financing to Liberated Syndication to facilitate Libsyn's recently announced acquisition of German podcast company Julep Media. The debt financing matures in 180 days.

08:24 EDT Cosmos Holdings announces pricing of $7.5M upsized public offering - Cosmos Holdings announced the pricing of its "reasonable best efforts" public offering of 62,500,000 shares of common stock, Series A Warrants to purchase 62,500,000 shares of common stock and Series B Warrant to purchase 62,500,000 shares of common stock at a combined price of $0.12 per share and warrant for aggregate gross proceeds of $7.5 million, before deducting placement agent fees and other offering expenses. The offering includes participation from Grigorios Siokas, CEO of Cosmos Holdings, Inc. as well as various Company advisors. The closing of the offering is expected to occur on or about October 20, 2022, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for its pending or potential acquisitions, payment of certain liabilities to existing warrant holders, as well as for working capital purposes and general corporate purposes.

08:23 EDT Puttshack signs new lease at Comstock's Reston Station - Puttshack, the world's only upscale, tech-infused mini golf experience with global food and drink, and Comstock Holding Companies, a developer, operator, and asset manager of mixed-use and transit-oriented properties in the Washington, D.C. region, announced y the signing of a new lease at 1850 Reston Row Plaza in Reston, Virginia, part of the Phase 2 development underway at Comstock's 80-acre Reston Station development. Located at the Wiehle-Reston East Metro Station, Puttshack will anchor the building as the first active entertainment venue at Reston Station when it opens in Summer 2025.

08:21 EDT Teva gives ARC-HD trial results on Austedo tolerability for Chorea in HD - Teva Pharmaceuticals announced results from the ARC-HD trial, an approximately 3-year open-label, single-arm, 2-cohort, multicenter extension study evaluating the safety and tolerability of long-term treatment with AUSTEDO or deutetrabenazine, tablets for chorea associated with Huntington's Disease . The ARC-HD study was conducted by Teva in partnership with the Huntington Study Group. ARC-HD results showed that treatment with AUSTEDO had a safety and tolerability profile comparable with the First-HD randomized, double-blind, placebo-controlled, 12-week study. In ARC-HD medication compliance rates were greater than 90% over the ~3 year open-label extension period. Over this full period, AUSTEDO improved and maintained chorea control in both the Rollover cohort and the Switch cohort, as measured by the Unified Huntington's Disease Rating Scale otal Maximal Chorea score "These data provide important insight into the long-term use of deutetrabenazine for the treatment of chorea associated with Huntington's disease, which can have a significant functional impact on people's lives," said Samuel Frank, MD, Associate Professor of Neurology and Director of HDSA Center of Excellence at Beth Israel Deaconess Medical Center, Boston, and lead author of the study. "Results of this study add to the safety and tolerability profile and support deutetrabenazine as a treatment choice for this progressive condition. We are deeply grateful to the researchers, patients and their families who played an integral role in this study."

08:20 EDT Telus Business launches ShopWithOwners.ca - TELUS Business is celebrating Small Business Month this October with the launch of ShopWithOwners.ca, a new online platform to connect Canadians with their favourite local shops, including past #StandWithOwners winners. This platform will help support business owners across the country with gaining exposure to customers looking for local finds and gifts during the holiday season. Canadians will be able to search by location, keywords and categories to discover exceptional small businesses they can easily support within their community. Visitors will be able to learn more about the owner, their business and be directed to their website and social media pages.

08:19 EDT LightJump Acquisition files registration statement on Form F-4 - Moolec Science and LightJump Acquisition announced the filing of a registration statement on Form F-4 by Moolec Science, which contains a preliminary proxy statement/prospectus, with the U.S. Securities and Exchange Commission in connection with their recently proposed business combination. While the Registration Statement, which can be found here, has not yet become effective, and the information contained therein is subject to change, it provides important information about Moolec's business and operations, proposed business combination with LightJump and the proposals to be considered by LightJump's stockholders. Completion of the proposed business combination, which is expected to close by the end of 2022, is subject to the Registration Statement being declared effective by the SEC, approval by LightJump's stockholders, and other customary closing conditions. The Combined Company, will be led by Mr. Gaston Paladini, Chief Executive Officer and Co-Founder of Moolec Science. Upon completion of the transaction, the Company is expected to become a public company listed on Nasdaq under the ticker symbol "MLEC". The business combination sets the Combined Company's proforma equity value at $394 million and as a result of the transaction, the Combined Company is expected to be funded with approximately $27 million in cash proceeds held in LightJump's trust account, assuming no further LightJump shareholders exercise their redemption rights at closing and before transaction-related expenses. In addition, LightJump has entered into a backstop agreement with entities affiliated with Moolec to guarantee a minimum of $10 million at closing.

08:18 EDT B. Riley Financial purchases second portfolio from Franchise Group subsidiary - B. Riley Financial (RILY) has purchased a second portfolio of performing receivables from W.S. Badcock, a home-furnishing retailer. Badcock is a subsidiary of Franchise Group (FRG), a franchise operator. B. Riley previously acquired $535M of performing Badcock receivables for approximately $400M in connection with FRG's acquisition of Badcock in December 2021. An SPV majority owned by B. Riley has purchased approximately $198M of Badcock's performing receivables for an aggregate purchase price of approximately $168M. The SPV has the option to purchase up to an additional $75M of receivables over the six months post-closing, subject to certain limitations. The SPV financed the transaction using a $148M senior secured term loan credit facility from Pathlight Capital, which included a limited guaranty of $15M from B. Riley. Badcock will continue to service and administer the purchased receivables.

08:15 EDT United Rentals to add several hydrogen power generators to North America fleet - United Rentals announced it is adding several hydrogen power generators to its North American rental fleet in the coming months. With the generators, United Rentals customers will have a zero-emissions power solution to charge electric vehicles and tools, and other equipment, advancing worksite electrification strategies. The EODev GEH2 fuel cell electro-hydrogen generators bring companies the energy they need, without emissions of carbon dioxide, hydrocarbons, nitrogen oxides or other particulate matter. With a compact footprint of about four feet by 11 feet, the generators deliver instant power up to 110 kVA. They are equipped with the latest hydrogen fuel cells, and provide exceptional durability and reliability. In addition to the sustainability benefits, they also run much quieter than traditional generators. United Rentals has acquired the generators from Generac, a distribution partner for EODev. The generators join emissions-free aerial lifts, trucks, vans, compact excavators, e-dumpsters, battery systems and more already in the United Rentals portfolio of environmentally friendly rental equipment. United Rentals expects to deploy the generators during the fourth quarter of 2022 and in 2023.

08:15 EDT Mayfair Gold announces updated MRE for Fenn-Gib Gold Project - Mayfair Gold announced an updated mineral resource estimate at the Company's 100% controlled Fenn-Gib Gold Project, located in the Timmins region of Northeast Ontario. Based on assay results from 61 percent of the Company's current 110,000-meter infill and expansion drill program, the Fenn-Gib deposit now hosts a NI 43-101 pit constrained Indicated mineral resource estimate of 3.06 million ounces gold and an Inferred mineral resource of 0.31M oz Au. The near-surface Fenn-Gib gold mineralization is broadly disseminated striking east-west on the Pipestone Fault over more than 1.25 kilometers and is up to 300m wide at the west end. Mayfair Gold President and CEO Patrick Evans commented: "With the expansion of the Fenn-Gib gold zones, the mineral resources have shown significant improvement over the previous estimates. Within 18 months of acquiring Fenn-Gib, Mayfair has increased the Indicated resource size by 47 percent. The Fenn-Gib mineralization remains open for expansion in most directions, and we are excited about the near-term potential to further increase the resources with the ongoing drill program supported by three drill rigs. A large portion of the incremental tonnes reported today come from the Expansion Zone in the center of the Fenn-Gib deposit and to the east of the higher-grade Main Zone. Previously poorly defined, the Expansion Zone has been the focus of Mayfair's drill program, supported by two of the three drill rigs, and has added significant tonnage to the Fenn-Gib mineral resources." The 30,000m Phase 3 infill and expansion drill program is ongoing with gold mineralization continuing to be intersected in all holes reported to date. Based on the continuing success, Mayfair expects to declare a further resource update in Q2 2023 on completion of the 110,000m drill program. The potential exists for a further significant increase in the Fenn-Gib resource. Highlights of the Updated Fenn-Gib Mineral Resource Estimate: Pit constrained Indicated resource: 47% increase in Au to 3,061,991 oz from 2,077,661 oz; Pit constrained Inferred resource: 315% increase in Au to 311,356 oz from 74,967 oz; Maiden underground resource: Inferred underground Au resource of 103,586 oz

08:12 EDT Semtech, Sierra Wireless receive additional information requests from DOJ - Semtech (SMTC) and Sierra Wireless (SWIR) announced that each company has received a request for additional information and documentary material from the U.S. Department of Justice, or DOJ, in connection with Semtech's previously announced acquisition of Sierra Wireless. The second requests were issued under notification requirements of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. Issuance of the second requests extends the waiting period under the HSR Act until 30 days after Semtech and Sierra Wireless have substantially complied with the second requests, unless that period is extended voluntarily by the parties or otherwise terminated by the DOJ. Semtech and Sierra Wireless believe the transaction will benefit customers of both companies and are cooperating fully with the DOJ in order to facilitate its review. Semtech and Sierra Wireless look forward to continuing to work with the DOJ to resolve their open questions and bring their review to a close. Of further note, Semtech received a no action letter from the Canadian Competition Bureau on October 3, satisfying the Competition Act Approval condition to closing. The parties are working to close the transaction as expeditiously as possible, within the timeframe initially provided under the arrangement agreement, which ends no later than March 3, 2023, unless extended further by mutual agreement of the parties.

08:12 EDT IntelGenx submits response to FDA CRL for RIZAPORT VersaFilm - IntelGenx announced that it has responded to the Complete Response Letter for its 505(b)(2) New Drug Application for RIZAPORT VersaFilm received from the U.S. Food and Drug Administration in March 2020. "We have been encouraged by our interactions with the FDA and are pleased to submit our response to the CRL," commented Dr. Horst G. Zerbe, CEO of IntelGenx. "Based on the feedback from our Type A meeting, we conducted additional product testing and believe that this response provides all of the additional Chemistry, Manufacturing and Controls information that the FDA required. We are looking forward to continuing to work with the Agency to make RIZAPORT VersaFilm available to acute migraine patients."

08:10 EDT Oracle, HSBC partner to accelerate digital transformation - Oracle (ORCL) and HSBC (HSBC) announced a strategic collaboration to accelerate the bank's digital transformation. Under the multi-year agreement, HSBC will upgrade and migrate select database systems to Oracle Exadata Cloud@Customer, a cloud platform delivered as a managed infrastructure service in HSBC's own data centers. The deployment will help support and scale the bank's mission-critical systems and services.

08:08 EDT Aerovate Therapeutics presents Phase 2b/Phase 3 IMPAHCT trial design - Aerovate Therapeutics presents the design of IMPAHCT, a Phase 2b/Phase 3 trial investigating the safety and efficacy of AV-101 in adults with pulmonary arterial hypertension, at the American College of Chest Physicians Annual Meeting in Nashville, TN. The IMPAHCT trial, which was initiated in December 2021, is a multi-national trial consisting of three parts: Part one: Part one, which is the Phase 2b portion of the trial, will assess the safety, tolerability, and efficacy of three twice-daily doses of AV-101 against placebo and establish an optimal dose for Phase 3. The primary endpoint for this part is change in pulmonary vascular resistance after 24 weeks compared to placebo. Part two: Part two begins immediately following enrollment of the last participant in the Phase 2b part of the trial and signifies the start of enrollment in the Phase 3 trial. Part two uses the same dosing as in the Phase 2b part of the trial with participants randomized across three AV-101 doses and placebo. Enrollment in part two will continue until the optimal AV-101 dose is selected based on results from the Phase 2b analysis. Part three: This part of the trial will start once an optimal dose of AV-101 has been selected based on the Phase 2b results. All patients enrolling during this part of Phase 3 will be randomized to either the optimal dose of AV-101 or placebo. The primary endpoint for Phase 3 is change in six-minute walk distance at 24 weeks for the optimal dose of AV-101 compared to placebo. In addition to PVR and 6MWD, multiple additional endpoints will be evaluated including changes in WHO Functional Class, REVEAL Lite 2.0 risk score, NT-proBNP, and quality of life along with assessments of clinical worsening, clinical improvement, safety and tolerability, and pharmacokinetics.

08:07 EDT Bombardier to inaugurate Miami-Opa Locka service center on Oct. 31 - Bombardier is pleased to announce that it will officially inaugurate its newest service centre in the U.S., located at the Miami-Opa Locka Executive Airport in Miami-Dade County, Florida. Bombardier's Leadership team, customers, VIP guests and members of the media will be invited to attend the ceremony on Oct. 31, 2022, in Miami. Once fully operational, the new 300,000 square foot facility will more than quadruple Bombardier's current maintenance footprint in Florida and allow the company to transfer its service centre operations from Fort Lauderdale to the new one-of-a-kind customer service centre at Miami-Opa Locka Executive Airport, located close to Miami's bustling business district. The new facility will be fully equipped to perform extensive and complete full-service scheduled and unscheduled heavy maintenance, including paint enhancement services, to help reduce aircraft downtime. It will be fully equipped to perform scheduled and unscheduled maintenance, aircraft modifications, avionics installations, and Aircraft on Ground Support for Bombardier's business aircraft fleet of Learjet, Challenger, and Global aircraft.

08:07 EDT Walmart launches new creator platform - Walmart announced the launch of a new platform designed around creators. The program is called Walmart Creator and it's a one-stop portal that makes it easy for creators to monetize shoppable products from the retailer. Creators who sign up will have access to tens of thousands of products and are given the opportunity to earn revenue all while earning commissions on sales they refer with no cap. Users of the platform can share product links to any social platform or group of their choice, receive product recommendations based on interests and affinities, and collect valuable performance data to help grow their community and following.

08:05 EDT Immix Biopharma approves 4 additional clinical trial sites for IMX-110 - Immix Biopharma announced that it has approved 4 additional clinical trial sites for IMX-110 clinical trials, complementing existing soft tissue sarcoma lead clinical trial site in California. Once dosing begins, patients will undergo CT scans every 8 weeks to assess tumor response to IMX-110; results are expected to be released on a rolling basis beginning in Q1 2023. "We are excited to select these 4 preeminent oncology sites to join our clinical site consortium from a larger group of interested centers. We are humbled by the enthusiasm from these key opinion leaders to bring IMX-110 to their patients," said Ilya Rachman, MD PhD, CEO of ImmixBio. "These KOLs are excited about both IMX-110 as a monotherapy, and in combination with BeiGene and Novartis' anti-PD-1, tislelizumab."

08:05 EDT Gentherm's ClimateSense Technology to launch on the 2024 Cadillac CELESTIQ - Gentherm announced that it has been selected by Cadillac to supply ClimateSense on the 2024 Cadillac CELESTIQ. CELESTIQ will be the first to market vehicle to feature a Gentherm ClimateSense four-zone microclimate system as standard equipment. "We are honored that the Cadillac CELESTIQ will feature the industry's first deployment of our ClimateSense system that offers advanced cabin climate technologies, electronics and software algorithms that help deliver luxurious, efficient and personalized comfort for every occupant," said Phil Eyler, Gentherm's President and CEO. "The ClimateSense system on the CELESTIQ marks a turning point in how automakers can view cabin comfort by providing rapid and efficient heating and cooling to the occupant while maximizing energy efficiency and optimizing driving range and comfort."

08:05 EDT Charles River and Nanoscope team on multifaceted gene therapy manufacturing - Charles River Laboratories and Nanoscope Therapeutics a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced a comprehensive manufacturing collaboration utilizing Charles River's extensive contract development and manufacturing, CDMO. services in both plasmid DNA and viral vectors. Through this partnership, Nanoscope will have access to established manufacturing platforms and multiple Charles River CDMO centers of excellence, leveraging a comprehensive range of services including, but not limited to, Good Manufacturing Practice cell banking, High Quality and GMP-grade plasmid DNA manufacture, and GMP adeno-associated virus production. This gene therapy manufacturing partnership builds on Charles River's acquisitions of Cognate BioServices, Cobra Biologics, and Vigene Biosciences in 2021 that expanded its comprehensive cell and gene therapy portfolio to span each of the major CDMO platforms - cell therapy, viral vector, and plasmid DNA production. "Nanoscope looks forward to working with Charles River to support our accelerated development program. We have high expectations for our program and are counting on Charles River leadership, resources and scale to deliver in this partnership." - Anil Lalwani, Vice President, CMC, Nanoscope Therapeutics

08:03 EDT FIS CEO Gary Norcross to switch roles to chairman, Stephanie Ferris to succeed - FIS announced the appointment of Stephanie Ferris as president and CEO. In addition to her current role as president, Ferris will take over as CEO from Gary Norcross who has served as the company's CEO for the last eight years and chairman since 2018. Ferris will assume the president and CEO role on January 1, 2023, when Norcross takes on the role of executive chairman of the board. Ferris was also appointed to the FIS board of directors. FIS also announced that Norcross, current CEO and chairman of the board of directors, will assume a new full-time role as executive chairman of the board.

08:03 EDT TD Holdings to acquire controlling interest in Shenzhen Tongdow for RMB650M - TD Holdings announced that on October 18, through its wholly-owned subsidiary, Shenzhen Baiyu Jucheng Data Technology Co., Ltd., and Shanghai Zhuotaitong Industry Co., have entered into an exclusive option agreement and a ten-year exclusive business cooperation agreement which provide the company the exclusive option to acquire a controlling interest of Shenzhen Tongdow Internet Technology Co., Ltd, an integrated service provider for an online to offline e-commerce commodities trading platform in China, and further propel the company's global commodities trading market presence. Pursuant to the Agreements, the company agrees to acquire 65% of the equity interests of STIT from SZIC in consideration of RMB650M in cash. The company also agrees to provide complete customer support, business support and related supply chain management services to STIT. The acquisition is subject to a fairness opinion and valuation report of STIT from an independent third party. Management expects the acquisition to be completed in a month. As the transaction proceeds, the company will publicly disclose required information either through press releases or SEC filings, as appropriate.

08:01 EDT Vir Biotechnology announces first patient dosed in Phase 2 trial of VIR-2482 - Vir Biotechnology announced that the first participant has been dosed in the Phase 2 PENINSULA trial evaluating VIR-2482 for the prevention of illness due to influenza A. This trial is the first to evaluate the role of a monoclonal antibody in the prevention of influenza A illness. "Each year, seasonal flu is responsible for hospitalizing millions of people around the world and causing hundreds of thousands of deaths," said Phil Pang, M.D., Ph.D., executive vice president, chief medical officer and interim head of research at Vir Biotechnology. "With current flu vaccine effectiveness rates averaging 40%, additional prevention approaches are urgently needed, especially for those at highest risk. VIR-2482 has been designed as a single, easy-to-administer intramuscular dose to provide immediate protection against influenza A for the duration of the flu season, and we believe that its broad strain coverage could provide consistent, year-over-year protection against both seasonal influenza A strains and future flu pandemics. VIR-2482 has the potential to fill a critical gap in the prevention of illness, and we look forward to learning more from this new Phase 2 trial."

07:47 EDT Australis Capital completes first New York cannabis harvest - Australis Capital is pleased to announce that the Company, together with its partner Hempire, has successfully completed its first harvest of adult use cannabis in New York State. Following the successful harvest, the Company has shipped its flower for processing and manufacturing into vapes and edibles. This process will be overseen by Anthony DeMeo. DeMeo currently also holds the position of co-chair of Commercial Extraction and Manufacturing at Oaksterdam University. The Company is in negotiations with dispensary license candidates to secure pre-sales of its product. The Office of Cannabis Management and Cannabis Control Board recently reiterated that the first adult-use marijuana sales will happen before 2023. Governor Kathy Hochul is also on record stating that the timeline remains on track, with about 20 dispensaries coming online per month after the initial launch.

07:44 EDT Nextech AR Solutions announces $6.7M 3D model purchase order - Nextech AR Solutions announced it has received its single largest purchaser order to date of $6.7 million from a NASDAQ 100 technology company. The 3D models related to this $6.7M order are to be delivered in the calendar year 2023. With the previously announced $700,000 3D model order to be delivered in Q4, 2022 the total new orders recently announced equals $7.4M. These new 3D model orders set the stage for record growth in its 3D modeling business for the foreseeable future. While $6.7M is the most substantial 3D modeling order Nextech AR has received to date, the Company is still in negotiations for additional significant 3D modeling contracts from large enterprise customers, which it expects to announce shortly.

07:42 EDT State Street intends to repurchase $1B of common stock in Q4 - O'Hanley concluded: "Our continued strong results generated excess capital, which we are committed to returning to our shareholders as evidenced by our intention to repurchase approximately $1 billion of common stock in the fourth quarter of 2022. This plan for significant share repurchases, coupled with the recently announced 10% per share increase in our quarterly common stock dividend underscores our earnings strength."

07:40 EDT Goldman Sachs CEO sees 'good chance' of recession - CEO David Solomon is speaking on CNBC.

07:38 EDT Monarch Mining announces additional results from Swanson gold project - Monarch Mining reports that it has received additional results from the 2021-2022 drilling program on its wholly-owned Swanson gold project, including more high-grade assays and wider mineralized zones. Comprising a contiguous group of 127 map-designated claims and one mining lease covering an area of 5,125.8 ha, the Swanson property lies 65 kilometres northeast of Val-d'Or, Quebec, and just 50 kilometres north of Monarch's wholly owned 750 tonne-per-day Beacon mill. "We continue to establish the continuity of the mineralized corridor at depth," said Jean-Marc Lacoste, President and Chief Executive Officer of Monarch. "These drill results push the limits of the mineralization even further out from the currently defined mineral resource envelope and the proposed pitshell."

07:37 EDT Weatherford enters into $370M amended, restated credit facility - Weatherford International announced that on October 17, 2022 certain of its wholly-owned subsidiaries entered into a credit agreement, which amended and restated the Company's existing secured letter of credit agreement, dated December 13, 2019, as amended. Total aggregate commitments under the Credit Facility are $370M of which $45M is available for revolving loans. The amount available for revolving loans can be increased by up to an additional $100M as the Company meets certain leverage ratios and subject to lenders' consent. The Credit Facility will allow the Company to transfer certain cash collateralized letters of credit to the Credit Facility, resulting in lower aggregate cash collateral requirements. The Credit Facility also provides the Company the flexibility, upon satisfaction of certain conditions, to request incremental increases in the aggregate commitments under the Credit Facility to not more than $600M. The maturity date under the Credit Facility is October 17, 2026, subject to certain conditions.

07:35 EDT FTI Consulting names Wrobel as Global Leader of ESG & Sustainability offering - FTI Consulting announced the appointment of Miriam Wrobel as Global Leader of the firm's growing ESG & Sustainability offering. Wrobel, a Senior Managing Director based in San Francisco, joined FTI Consulting in 2021 and advises clients on ESG and energy transition strategy, transaction structuring and due diligence. She will lead a diversified team of professionals across FTI Consulting's global network who work on ESG and sustainability-related matters.

07:34 EDT Lockheed Martin announces additional $14B in share repurchase authority - On October 17, the company's board authorized the purchase of up to an additional $14B of Lockheed Martin common stock under its share repurchase program. This multi-year share repurchase program follows the substantial completion of purchases of common stock under the prior repurchase authorization. The company anticipates executing a $4B accelerated share repurchase program in the fourth quarter, bringing the total share repurchases for the year to approximately $8B. The remainder of the repurchase program authorization is expected to be utilized over a three-year period. The company expects to fund the repurchases through a combination of cash on hand and the issuance of debt.

07:33 EDT iKena Oncology provides research, development update on IK-930 program - Ikena Oncology (IKNA) provided a research & development update on the Company's lead targeted oncology program in TEAD inhibition. Ikena also announced a clinical trial collaboration agreement with AstraZeneca (AZN) for the evaluation of TAGRISSO, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor, in combination with Ikena's IK-930 as treatment for patients with EGFR-mutated non-small cell lung cancer. "Patients with Hippo-altered cancers are in need of therapies that are effective, safe, and significantly improve their quality of life. IK-930 is specifically designed as a paralog-selective TEAD inhibitor that has the potential to provide patients with a differentiated treatment option," said Mark Manfredi, PhD, Chief Executive Officer of Ikena. "As a first in its class, IK-930's selectivity profile has potential to distinguish itself not only as a monotherapy, but in combination with other targeted therapies where resistance has emerged. I am thrilled AstraZeneca shares in this vision and that we will be exploring IK-930 in combination with osimertinib." The ongoing IK-930 clinical trial has planned cohorts exploring combinations with targeted therapies in which treatment-induced activation of the Hippo pathway may drive resistance. The first combination cohort will be evaluating IK-930's potential to overcome resistance to EGFR inhibitors. Preclinical results demonstrate that IK-930 combined with osimertinib results in increased induction of apoptosis and improved anti-tumor activity in multiple EGFRm tumor models. This benefit is mediated in part by the Hippo pathway's role in the proliferation of persister cells, a subpopulation of cancer cells that drive EGFR resistance through TEAD-mediated induction of genes involved in cell cycle re-entry, DNA replication and apoptosis avoidance. Further data on the effectiveness and differentiation of IK-930 in multiple animal models both as a monotherapy and in combination with other targeted therapies will be presented at upcoming conferences, and initial clinical data from the first in human Phase 1 study are expected in 2023.

07:32 EDT Lockheed Martin reports increased backlog to $140B

07:32 EDT Goldman Sachs jumps 1.4% in premarket trading following release of Q3 results

07:32 EDT Goldman Sachs CEO: Fundamentals not changing with reorganization - CEO David Solomon is speaking on CNBC.

07:31 EDT Lockheed Martin announces additional $14B in share repurchase authority

07:30 EDT Goldman Sachs CEO tells CNBC that operating environment is 'challenging' - David Solomon tells CNBC in an interview that M&A activity is still "relatively robust."

07:28 EDT Goldman Sachs announces realignment of businesses - Chairman and CEO David Solomon said: "In January 2020, we outlined our strategy in clear and direct terms, introducing a plan to grow and strengthen our core businesses, diversify our products and services, and operate more efficiently as we drive higher, more durable returns. Today, we enter the next phase of our growth, introducing a realignment of our businesses that will enable us to further capitalize on the predominant operating model of One Goldman Sachs as we better serve our clients."

07:25 EDT Goldman Sachs reports Q3 annualized ROE 11%, annualized ROTE 12% - Reports Q3 book value per share $308.22.

07:21 EDT Laser Photonics introduces new MARLIN line of products - Laser Photonics introduced the soon to be released MARLIN, or Marine Application Rust Laser Inhibitor, line of products. The Company expects the first MARLIN product to be commercially available before the end of the year.

07:19 EDT Silo Pharma enters rsearch collaboration with Columbia University - Silo Pharma announced it has entered into an agreement with Columbia University pursuant to which Silo has been granted an extension for its option to license certain assets currently under development, including Alzheimer's disease and Stress Induced Anxiety. The extension to the agreement incorporates the work of Dr. Christine Ann Denny, an Associate Professor of Clinical Neurobiology at Columbia University Irving Medical Center. Denny and her team are focusing their efforts on the molecular mechanisms underlying learning and memory, including diseases such as Alzheimer's disease. An estimated 5.8 million Americans, including one in ten people, age 65 and older, currently live with Alzheimer's disease. Dr. Denny's pioneering research into whether ketamine and the novel inventions that may be licensed by Silo may improve memory retrieval, halt, or even reverse, the process of Alzheimer's disease-related to memory loss or cognitive aging, could have life-altering implications for people suffering with everything from Alzheimer's disease to post-traumatic stress disorder. On-going research studies are currently being conducted by Silo.

07:14 EDT Alta Equipment Group to acquire Evercore in in highly accretive' deal - Alta Equipment Group announced that it has entered into a definitive agreement to acquire Ecoverse Industries , a full line distributor of industry-leading environmental processing equipment headquartered in Avon, Ohio, with 15 sub dealers throughout North America. "The acquisition of Ecoverse is exciting for our business as it represents our first investment into large-scale equipment distribution, giving us the master dealer rights to distribute best-in-class environmental equipment to dealers and customers throughout North America," said Ryan Greenawalt, Chief Executive Officer of Alta. "Ecoverse has a long standing track record in the environmental processing equipment sector as a distributor of high-end equipment which is used in biofuel, composting, and various waste and recycling applications. The Ecoverse acquisition immediately positions Alta as an industry leader in a sector where demand for eco-friendly waste solutions and recycling continues to grow. We welcome Ecoverse to the Alta family." The purchase price includes $42.5M in cash, $2.M of Alta common stock and a $6M million seller note, at close. In addition, the purchase price includes contingent consideration in the form of an earn-out whereby sellers can earn an additional $4M of Alta common stock and $1M of cash over a five-year period subject to future EBITA growth. To the extent EBITA remains flat at July 2022 trailing twelve-month levels throughout the earn-out period, the total purchase price will be $59M. Other iterations of the ultimate purchase price range from $51M to $67M based on future EBITA performance. The transaction is subject to customary closing conditions and is expected to close in the fourth quarter of 2022. Including Ecoverse, since the Company's initial public offering in 2020, Alta has completed 13 acquisitions which have contributed $440.3M in revenue, and $52.5M in Adjusted EBITDA.

07:12 EDT Rockwell Automation and Cognite form strategic partnership for data hub - Rockwell Automationand Cognite, a global leader in industrial data software, announced a strategic partnership to further unlock the value of manufacturing data and accelerate technological change for the industry. The partnership combines Rockwell's FactoryTalk software offering of next-generation edge connectivity to plant assets, operations management applications, and industry-tailored analytics with Cognite's leading Industrial DataOps platform, Cognite Data Fusion , to create an industrial data hub ready for enterprise-wide scaling. With one of the largest footprints in industrial automation, Rockwell products create and process data worldwide. The partnership between Rockwell and Cognite will bring to market a unique, unified, edge-to-cloud industrial data hub that makes operational, engineering, enterprise, and visual data understandable and comparable for manufacturing across industries. The offering will transform raw data into high-impact applications for real-time decision making and improved workflows that ensure safe, productive, and sustainable operations. With Cognite's proven success in the Energy industry, this partnership will further enhance the edge-to-enterprise capabilities from Sensia, Rockwell's joint venture with Schlumberger.

07:11 EDT Doral Renewables secures up to $1.1B of growth capital commitments - Doral Renewables entered into an agreement to sell up to $500M of convertible notes to funds managed by Apollo affiliates and Migdal Insurance. The Notes are convertible to common equity interests in the company at a pre-money valuation of $1.5B. Doral intends to use the proceeds from the transaction to fund investments in renewable energy and storage projects being developed by the Company. In connection with the investment, Apollo partner Corinne Still will join the Company's Board.

07:09 EDT Atai Life Sciences announces initiation of Phase 1 trial for intranasal INB-01 - atai Life Sciences announced the initiation of the Phase 1 proof-of-concept, PoC, clinical trial of intranasal INB-01, a sol-gel based, excipient technology. This is a Phase 1 two-stage, open-label, randomized study of the safety, tolerability, and effective brain delivery of INB-01. INB-01 or placebo will be administered to subjects using the Aptar Nasal Drug Delivery Device. Topline results are expected in H1 2023. "Exploring the mechanism of drug delivery is an opportunity for us to further enhance the treatment experience," said Florian Brand, Co-Founder, and CEO of atai Life Sciences. "INB-01 has the potential to provide superior drug uptake via the nose-brain barrier, reducing dose administered and dosing frequency. We are confident this will help patients and healthcare practitioners by easing administration, dosing, and providing faster relief to improve compliance."

07:08 EDT Alta Equipment Group to but Evercore in in highly accretive' deal - Alta Equipment Group announced that it has entered into a definitive agreement to acquire Ecoverse Industries, , a full line distributor of industry-leading environmental processing equipment headquartered in Avon, Ohio, with 15 sub dealers throughout North America. "The acquisition of Ecoverse is exciting for our business as it represents our first investment into large-scale equipment distribution, giving us the master dealer rights to distribute best-in-class environmental equipment to dealers and customers throughout North America," said Ryan Greenawalt, Chief Executive Officer of Alta. "Ecoverse has a long standing track record in the environmental processing equipment sector as a distributor of high-end equipment which is used in biofuel, composting, and various waste and recycling applications. The Ecoverse acquisition immediately positions Alta as an industry leader in a sector where demand for eco-friendly waste solutions and recycling continues to grow. We welcome Ecoverse to the Alta family." The purchase price includes $42.5M in cash, $2.M of Alta common stock and a $6M million seller note, at close. In addition, the purchase price includes contingent consideration in the form of an earn-out whereby sellers can earn an additional $4M of Alta common stock and $1M of cash over a five-year period subject to future EBITA growth. To the extent EBITA remains flat at July 2022 trailing twelve-month levels throughout the earn-out period, the total purchase price will be $59M. Other iterations of the ultimate purchase price range from $51M to $67M based on future EBITA performance. The transaction is subject to customary closing conditions and is expected to close in the fourth quarter of 2022. Including Ecoverse, since the Company's initial public offering in 2020, Alta has completed 13 acquisitions which have contributed $440.3 million in revenue, and $52.5 million in Adjusted EBITDA.

07:08 EDT Pacific Avenue acquires Sunrich Products from SunOpta, terms not disclosed - Pacific Avenue Capital Partners has acquired Sunrich Products, the sunflower and roasted snack division of SunOpta. The transaction includes three processing facilities in the upper Midwest, hybrid seed development activities, a collaborative program with independent sunflower growers, and relationships with an extensive set of customers in the food ingredients, snack food, and birdseed markets. Kent Johnson, general manager of Sunrich, will become CEO. Kent will be joined by the rest of Sunrich's leadership team and employee base, ensuring quality products and reliable customer service.

07:06 EDT Conn's announces CEO Holt stepped down from position, Miller named interim CEO - Conn's announced that President and Chief Executive Officer Chandra Holt has stepped down from her position and from the Company's Board effective immediately. Effective immediately, Norman Miller will serve as Interim President and Chief Executive Officer. Miller was the Company's former President and Chief Executive Officer from September 2015 to August 2021 and Executive Chairman from August 2021 until April 2022, and has been a member of the Board of Directors since September 2015.

07:05 EDT Mereo BioPharma targets 40% reduction in headcount, expense reductions - Mereo BioPharma Group provided an update to its operating plan and programs. With this go-forward operating plan, Mereo will maintain the ability to progress its core programs, deliver on multiple near-term milestones and maximize value for shareholders. The updated plan extends the Company's cash runway into 2026. The Company will retain the core capabilities and key personnel needed to advance its two core rare disease programs and to generate value from its assets. With a targeted reduction in the employee base of up to 40% and a significant reduction in other costs, the Company will operate at what it believes to be the minimum level of resources currently required to continue executing on its strategy whilst remaining publicly listed. As of June 30, 2022, the Company had approximately GBP 76 million in cash on hand. As a result of these actions, the Company's cash runway has been further extended into 2026 from its previous guidance of into Q2 2025. Additionally, Mereo provided updates on its lead programs: Setrusumab - Setrusumab is currently being studied in an ongoing Phase 2/3 registrational trial in patients aged 5-25 with Osteogenesis Imperfecta being conducted by its partner, Ultragenyx. A protocol amendment for the Phase 2 part of the study removes the placebo arm and continues evaluating the same two dose levels of setrusumab as in the original protocol. This amendment has been submitted to the U.S. Food and Drug Administration and is now subject to approval by the site-specific Institutional Review Boards. Ultragenyx currently expects to complete enrollment in this portion of the study in the next few months, and to transition to the Phase 3 portion in the first half of 2023. Further, Ultragenyx plans to initiate a pediatric study in patients with OI aged 2 to less than5 years, also in the first half of 2023. This program is, and will remain, the main focus of Mereo's capital resources. Alvelestat - An R&D Update on the alvelestat program for alpha-1-anti-trypsin deficiency has been scheduled for 8:00 am ET on October 31, 2022. This update will include commentary from and Q&A with leading pulmonology experts, further to the receipt of Fast Track Designation from the FDA announced yesterday.Etigilimab - In the ongoing Phase 1b/2 study in combination with nivolumab, the Company reported that 16 patients remain on study and responding to therapy. As previously announced, the study continues to be wound down as patients' disease progresses, requiring less of the Company's resources, and will terminate once all patients have disease progression or have left the study. "Our revised operating plan seeks to retain key personnel and conserve shareholder capital as we work to maximize the value of our promising rare disease programs for our shareholders, who share our conviction in these assets and their potential to create positive outcomes for patients and their families," said Dr. Denise Scots-Knight, CEO. "With the changes Ultragenyx has made to the setrusumab development plan, the recent Fast Track designation for alvelestat for AATD and important milestones for our two core programs approaching over the next year or so, we believe this revised plan successfully positions Mereo for the future. I would like to thank all the affected employees for their dedication to developing potential treatments for patients with rare diseases and cancer."

07:03 EDT MycoWorks secures strategic investment from GM Ventures - MycoWorks announced its newest investor GM Ventures, the investment arm of General Motors, and their long-term agreement to co-develop Fine Mycelium materials for potential use in a range of applications within automotive design. MycoWorks' collaboration with GM marks the exploration of its entry into one of the largest end-use markets for leather and demonstrates the significant opportunity to create more sustainable materials for the automotive space.

07:02 EDT Instil Bio announces first patient dosed with ITIL-306 - Instil Bio announced that the first patient has been dosed in a Phase 1 dose escalation study of ITIL-306 for the treatment of multiple solid tumors. ITIL-306 is Instil's first genetically-engineered Costimulatory Antigen Receptor-TIL therapy. "The successful initiation of the Phase 1 study of ITIL-306 underscores our commitment to evolving TIL therapy, using strategies to enhance product efficacy and safety, with the goal to achieve durable remissions in patients with treatment-refractory solid tumors," said Bronson Crouch, Chief Executive Officer of Instil Bio. Instil's first-in-human Phase 1 study of ITIL-306 is an open-label, multicenter study in patients with non-small cell lung cancer, ovarian cancer, and renal cell carcinoma. Patients in the first dose cohort will receive a target dose of one billion CoStAR-transduced TILs after receiving a reduced intensity lymphodepletion regimen and no post-infusion interleukin-2. The study will evaluate safety of ITIL-306 in addition to efficacy and translational endpoints. The company anticipates reporting initial clinical data from the Phase 1 trial in 2023.

06:58 EDT Pzena Investment's going-private transaction recommended by Glass Lewis - Pzena Investment announced that independent proxy advisory firm Glass Lewis has recommended that stockholders vote "for" the adoption of the merger agreement pursuant to which Pzena will become a private company. ISS has also recommended voting in support of the transaction. The special meeting of stockholders to vote on the transaction will take place virtually on October 27. In its report, Glass Lewis noted: "... the implied premiums relative to historical trading levels indicate an attractive purchase price...the special committee's determination that it would be unlikely for a superior offer to emerge from a potential third party is reasonable, given that the transaction involves the acquisition of only a minority stake in a controlled company... now may be an appropriate time for the company's unaffiliated public shareholders to realize a certain value and full liquidity at a price that appears to be reasonable from a long-term fundamental value perspective." The transaction is expected to close in Q4, subject to approval by PZN stockholders, including a special approval of holders of a majority of the Class A shares not held by persons who will remain as investors in PIM following the closing.

06:55 EDT Eli Lilly to acquire Akouos for $12.50 per share, one CVR up to $3.00 per share - Eli Lilly (LLY) and Akouos (AKUS) announced a definitive agreement for Lilly to acquire Akouos, a precision genetic medicine company that is developing a portfolio of adeno-associated viral gene therapies for the treatment of inner ear conditions, including sensorineural hearing loss. Under the terms of the transaction, Lilly will acquire all of the outstanding shares of Akouos for $12.50 per share in cash, plus one contingent value right, or CVR, of up to $3.00 per share. The deal has been approved by the boards of directors of both companies. Lilly will commence a tender offer to acquire all outstanding shares of Akouos for a purchase price of $12.50 per share in cash payable at closing plus one non-tradeable contingent value right per share, or CVR, that entitles the holder to receive up to an additional $3.00 in cash, for a total consideration of up to $15.50 per share in cash without interest . CVR holders would become entitled to receive contingent payments as follows: $1.00 in cash, upon the fifth participant being administered with AK-OTOF in a Phase 1 or Phase 1/2 trial on or prior to Dec. 31, 2024; $1.00 in cash, upon the fifth participant being administered with an Akouos gene therapy product for a second monogenic form of sensorineural hearing loss on or prior to December 31, 2026; and $1.00 in cash, upon the first participant being administered with an Akouos gene therapy product for a monogenic form of sensorineural hearing loss in a Phase 3 trial, or receipt of FDA approval in the U.S. for such Akouos product, whichever occurs first, on or prior to December 31, 2026, or its value will be reduced by approximately 4.2 cents per month until December 1, 2028. There can be no assurance that any payments will be made with respect to the CVR. The transaction is not subject to any financing condition and is expected to close in the fourth quarter of 2022, subject to customary closing conditions, including receipt of required antitrust clearance and the tender of a majority of the outstanding shares of Akouos's common stock. Following the successful closing of the tender offer, Lilly will acquire any shares of Akouos that are not tendered in the tender offer through a second-step merger at the same consideration as paid in the tender offer. The purchase price payable at closing represents a premium of approximately 121% to the 30-day volume-weighted average trading price of Akouos's common stock ended on Oct. 17, 2022, the last trading day before the announcement of the transaction. Akouos's board unanimously recommends that Akouos's stockholders tender their shares in the tender offer. Additionally, certain Akouos stockholders, beneficially owning approximately 26% of Akouos's outstanding common stock, have agreed to tender their shares in the tender offer. Lilly will determine the accounting treatment of this transaction as a business combination or an asset acquisition, including any related acquired in-process research and development charges, according to Generally Accepted Accounting Principles, or GAAP, upon closing, which is expected to occur in the fourth quarter of 2022. This transaction will thereafter be reflected in Lilly's financial results and financial guidance.

06:53 EDT NovaBay announces significant orders for DERMAdoctor Kakadu C - NovaBay Pharmaceuticals announces significant orders for DERMAdoctor Kakadu C 20% Vitamin C Serum with Ferulic Acid & Vitamin E. "We are excited to share that one of our best-selling products, DERMAdoctor Kakadu C serum, continues its popularity this year with several large orders just in time for the holiday season," said Justin Hall, NovaBay CEO. "These orders will favorably impact DERMAdoctor's revenue contribution for the 2022 third and fourth quarters."

06:48 EDT Merck and Bill & Melinda Gates MRI enter licensing agreement for tuberculosis - Merck and the Bill & Melinda Gates Medical Research Institute or MRI announced a licensing agreement for two preclinical antibacterial candidates for evaluation as potential components of combination regimens for the treatment of tuberculosis. These candidates were discovered by Merck scientists as part of the TB Drug Accelerator. The TBDA is a collaboration established among biopharmaceutical companies, research organizations and universities to accelerate the discovery and development of novel therapeutic candidates against TB. The initiative was established with support and leadership from the Bill & Melinda Gates Foundation. Merck has granted the Gates MRI an exclusive global license for MK-7762 and MK-3854. In furtherance of its charitable purpose, Gates MRI will conduct non-clinical and clinical studies of these candidates to determine their potential for inclusion in new affordable combination treatment regimens for TB with the aim of shortening the duration of treatment irrespective of resistance to the currently available TB drugs. In vitro and in vivo evaluation of MK-7762 and MK-3854 have shown that both candidates have potent antibacterial activity against Mycobacterium tuberculosis, the organism that causes tuberculosis.

06:37 EDT Genmab reports Q3 worldwide net sales of DARZALEX $2.05B - Genmab (GMAB) announced that worldwide net trade sales of DARZALEX, including sales of the subcutaneous ( product, as reported by Johnson & Johnson (JNJ) were $2.052B in the third quarter. Net trade sales were $1.097B in the U.S. and USD 955 million in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC products, under the exclusive worldwide license to Janssen to develop, manufacture and commercialize daratumumab.

06:09 EDT Coherent appoints Julie Sheridan Eng as Chief Technology Officer - Coherent appointed Julie Sheridan Eng, previously Senior VP and General Manager of Optoelectronic Devices and Modules, as Chief Technology Officer. Prior to being named CTO, Eng successfully ran the Optoelectronic Devices and Modules Business Unit. Previous to Coherent, Eng held a number of senior management positions at Finisar Corporation since 2003, including Executive Vice President and General Manager of 3D Sensing and Executive Vice President of Datacom Engineering.

06:07 EDT Acutus Medical submits premarket approval application for AcQBlate - Acutus Medical submitted pivotal clinical data from the AcQForce Flutter trial designed to gain marketing approval from the FDA for the AcQBlate Force Sensing Ablation Catheter and System or AcQBlate FORCE. Catheter ablation procedures to treat right atrial flutter account for approximately 30% of ablations in the US and are expected to reach 200,000 by 2025. The AcQForce Flutter trial enrolled 110 patients and was designed to evaluate the safety and efficacy of the AcQBlate FORCE sensing ablation catheter and system in the treatment of right atrial typical flutter. Primary endpoints were acute procedural success defined as bidirectional CTI block, and freedom from serious adverse events seven days post procedure. The primary efficacy endpoint was achieved, and the study observed no serious adverse events.

06:05 EDT AppTech Payments announces partnership with Chip Financial - AppTech Payments announced its partnership with Chip Financial to support the company's growing Fintech, digital banking and payments ecosystem. The partnership enhances Chip Financial's suite of solutions that focus on a tailored customer approach to provide capabilities in Payments-as-a-Service and Banking-as-a-Service. Chip Financial provides a variety of clients with flexible omni-channel transactions across a full spectrum of brand sectors. The partnership between AppTech and Chip Financial enables further market reach and penetration to extend AppTech's portfolio of commerce solutions.

06:05 EDT Roche confirms outlook for 2022

06:04 EDT Illumina enters partnership with GenoScreen in effort to end tuberculosis - Illumina and GenoScreen announced a partnership to accelerate progress to end tuberculosis, or TB, worldwide. The partnership will expand capabilities for countries most impacted by tuberculosis to more effectively detect and combat multidrug-resistant TB, or MDR-TB. This alliance will enable global access to a package combining Illumina sequencing products and the GenoScreen Deeplex Myc-TB assay, a targeted next-generation sequencing, or NGS, based test for rapid and extensive detection of anti-TB drug resistance, to promptly inform treatment decision. This will help advance the World Health Organization's, or WHO, strategy to end the global TB epidemic by 2035.

06:02 EDT Hercules Capital raises quarterly cash distribution to 36c per share - The following shows the key dates of the third quarter distribution payment: Record date of November 10; Payment date of November 17.

05:35 EDT Amazon Web Services to open infrastructure region in Thailand - Amazon Web Services, or AWS, an Amazon company, announced plans to open an infrastructure region in Thailand. The new AWS Asia Pacific Region will consist of three availability zones, adding to the existing 87 availability zones across 27 geographic regions. Globally, AWS has now announced plans for 24 more availability zones across eight more AWS Regions in Australia, Canada, India, Israel, New Zealand, Spain, Switzerland, and Thailand. The upcoming AWS Region in Thailand will enable developers, startups, and enterprises, as well as government, education, and nonprofit organizations, to run their applications and serve end users from AWS data centers located in Thailand, ensuring that customers who want to keep their data in Thailand can do so. In addition, as part of its commitment to the region, AWS plans an estimated investment of more than $5B in Thailand over 15 years.

05:27 EDT Becton Dickinson, Biocorp enter self-administered drug therapies tracking pact - Becton Dickinson and Biocorp announced that they have signed an agreement with the aim of using connected technology to track adherence for self-administered drug therapies, like biologics. The two companies will integrate Biocorp's Injay technology - a solution designed to capture and transmit injection events using Near Field Communication, or NFC, technology to the BD UltraSafe Plus Passive Needle Guard used with prefillable syringes.

05:20 EDT Daqo New Energy subsidiaries sign five-year polysilicon supply agreement - Daqo New Energy announced that its subsidiaries XinjiangDaqo and Inner Mongolia Daqo had signed a five-year high-purity polysilicon supply agreement with a solar manufacturing company in China. Under the supply agreement, Xinjiang Daqo and Inner Mongolia Daqo will provide this leading manufacturing company with a total amount of 46,200 MT high-purity mono-grade polysilicon from January 1, 2023 to December 31, 2027. Actual prices will be negotiated by both parties monthly according to market conditions.

05:09 EDT Genius Sports enters official data, integrity partnership with APL - Genius Sports has been selected as the exclusive Official Data Partner of the Isuzu UTE A-League Men, or ALM, and Liberty A-League Women, or ALW, 2022-23 season as part of a wide-ranging new partnership with the Australian Professional Leagues, or APL. This partnership will help to protect Australian soccer from the threats of match-fixing and betting-related corruption through Genius Sports' 24/7 bet monitoring technology and bespoke educational services. Under the terms of the agreement, Genius Sports has been granted the exclusive rights to capture, manage and distribute official data from every A-Leagues match and distribute it to its global network of sportsbook partners. Genius Sports is the official data and integrity partner to sports including the NFL and English Premier League. The A-Leagues have also committed to deploying Genius Sports' optical tracking systems in select venues with more details to follow later in the season.